放射性碘难治性滤泡型与嗜酸细胞型甲状腺癌的临床及组织病理学危险因素
该回顾性研究纳入荷兰Erasmus MC 2000至2016年治疗的90例滤泡型(FTC)和52例嗜酸细胞型(OTC)甲状腺癌成人患者,经组织病理学复核并按2015年美国甲状腺协会指南定义放射性碘难治性疾病。中位随访8.5年,14例FTC(15.6%)和22例OTC(42.3%)出现放射性碘难治。FTC的危险因素主要为原发肿瘤组织病理学特征,OTC则以淋巴结和远处转移为主。
要点
- FTC中放射性碘难治的危险因素包括诊断年龄较大、pT3/pT4分期、N1分期、广泛浸润和甲状腺外侵犯。
- OTC中N1和M1分期是最强危险因素,而非原发肿瘤的组织病理学特征。
- OTC患者出现放射性碘难治所需周期数少于FTC(2.0 vs 2.5),且10年疾病特异性生存率更低(46.4% vs 85.7%)。
核心结论
- 在FTC中,放射性碘难治的危险因素主要是原发肿瘤的组织病理学特征;而在OTC中,淋巴结和远处转移与放射性碘难治相关。
- 作者认为这些数据有助于临床决策,尤其对存在放射性碘难治风险的患者。
研究设计与样本
- 回顾性纳入荷兰Erasmus MC 2000至2016年治疗的90例FTC和52例OTC成人患者。
- 采用2015年美国甲状腺协会指南定义放射性碘难治性疾病,并应用2022年世界卫生组织分类通过荷兰病理数据库(PALGA)进行广泛组织病理学复核。
- 采用逻辑回归按组织学亚型分层识别放射性碘难治的危险因素。
主要发现
- 中位随访8.5年,14例FTC(15.6%)和22例OTC(42.3%)出现放射性碘难治性疾病。
- OTC出现放射性碘难治所需周期数为2.0(四分位距1.0-2.0),FTC为2.5(四分位距2.0-3.75)。
- 放射性碘难治显著降低10年疾病特异性生存率,OTC为46.4%,FTC为85.7%。
- FTC的危险因素为诊断年龄较大、pT3/pT4分期、N1分期、广泛浸润和甲状腺外侵犯。
- OTC中N1和M1分期是最强危险因素,而非原发肿瘤的组织病理学特征。
关键数值与推荐
- 放射性碘难治性疾病定义采用2015年美国甲状腺协会指南。
- 组织病理学分类采用2022年世界卫生组织分类。
临床怎么用
- 作者认为这些数据有助于临床决策,尤其对存在放射性碘难治风险的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Risk factors for radioactive iodine (RAI)-refractory disease in follicular (FTC) and oncocytic thyroid carcinoma (OTC) are unknown. OBJECTIVE: The aim of this study is to identify clinical and histopathological risk factors for RAI-refractory disease in FTC and OTC patients, facilitated by an extensive histopathological revision. METHODS: All adult FTC and OTC patients treated at Erasmus MC (the Netherlands) between 2000 and 2016 were retrospectively included. The 2015 American Thyroid Association guidelines were used to define RAI-refractory disease. An extensive histopathological revision was performed applying the 2022 World Health Organization Classification using PALGA, the Dutch Pathology Databank. Logistic regression was used to identify risk factors for RAI-refractory disease, stratified by histological subtype. RESULTS: Ninety FTC and 52 OTC patients were included, of whom 14 FTC (15.6%) and 22 OTC (42.3%) patients developed RAI-refractory disease over a follow-up time of 8.5 years. RAI-refractory disease occurred in OTC after fewer cycles than in FTC (2.0 [interquartile range (IQR): 1.0-2.0] vs 2.5 [IQR: 2.0-3.75]), and it substantially decreased 10-year disease-specific survival, especially in OTC (46.4%; FTC 85.7%). In FTC, risk factors were higher age at diagnosis, pT3/pT4 stage, N1 stage, widely invasive tumors, and extrathyroidal extension. N1 stage and M1 stage were the strongest risk factors in OTC, rather than histopathological characteristics of the primary tumor. CONCLUSION: To our knowledge, this is the first study that correlates clinical and histopathological risk factors with RAI-refractory disease in FTC and OTC, facilitated by a histopathological revision. In FTC, risk factors for RAI-refractory disease were foremost histopathological characteristics of the primary tumor, whereas in OTC presentation with lymph node and distant metastasis was associated with RAI-refractory disease. Our data can help clinical decision-making, particularly in patients at risk for RAI-refractory disease.
引用
- Stegenga MT, van Velsen EFS, Oudijk L, et al. Clinical and Histopathological Risk Factors for Radioactive Iodine-Refractory Follicular and Oncocytic Thyroid Carcinoma. J Clin Endocrinol Metab. 2024. PMID: 38349206. doi:10.1210/clinem/dgae084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。